Free tool
FAERS Monitor: Nexviazyme
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761194 or its brand name (Nexviazyme, Avalglucosidase Alfa-Ngpt). Reports on generic versions are filed under their own applications.
Reports
998
Serious
210
21% of reports
Hospitalization
113
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug specific antibody present150
- off label use100
- weight increased64
- inappropriate schedule of product administration52
- weight decreased46
- pyrexia39
- fatigue36
- dyspnoea35
- condition aggravated32
- illness32
- fall28
- headache28
- pneumonia26
- cough24
- malaise24
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 22 |
| 2022 | 148 |
| 2023 | 195 |
| 2024 | 212 |
| 2025 | 221 |
| 2026 | 200 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,161 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug specific antibody presentSignal | 150 | 497.5 | 428.4 | 72,155 |
| illnessSignal | 32 | 6.5 | 4.7 | 146 |
| inappropriate schedule of product administrationSignal | 52 | 6.1 | 4.7 | 218 |
| weight increasedSignal | 64 | 6.0 | 4.8 | 266 |
| weight decreasedSignal | 46 | 3.5 | 2.6 | 80 |
| off label useSignal | 100 | 2.4 | 2.0 | 84 |
| pyrexiaSignal | 39 | 2.4 | 1.7 | 30 |
| condition aggravatedSignal | 32 | 2.2 | 1.6 | 21 |
| cough | 24 | 1.8 | 1.2 | 8 |
| fall | 28 | 1.8 | 1.2 | 9 |
| pneumonia | 26 | 1.7 | 1.2 | 7 |
| dyspnoea | 35 | 1.3 | 0.9 | 2 |
| malaise | 24 | 1.2 | 0.8 | 0 |
| fatigue | 36 | 1.0 | 0.7 | 0 |
| headache | 28 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.